Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Linperlisib + Azacitidine + Liposomal Mitoxantrone in Treatment-Naïve Nodal TFH Cell Lymphoma
ChiCTR2500107944Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linperlisib, azacitidine and mitoxantrone hydrochloride liposome in follicular T-cell lymphoma (FTCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
linperlisibazacitidinemitoxantrone hydrochloride liposome
03
Conditions
follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on ChiCTR2500107944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107944.